Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides

Nuclear Medicine and Biology

Volumn 35, Issue 8, 2008, Pages 839-849

  Breeman, Wouter A P ^a   Froberg A C ^a   de Blois, E ^a   van Gameren, A ^a   Melis, M ^a   de Jong, M ^a   Maina, T ^b   Nock, B A ^b   Erion, J L ^c   Macke H R ^d   Krenning, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c BioSynthema Inc   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CCK; DOTA; Kidney uptake; Medullary thyroid carcinoma; Minigastrin; Receptor scintigraphy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CHOLECYSTOKININ IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEMOGASTRIN 2 TC 99M; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO GLUTAMYLALANYLTYROSYLGLYCYLTRYPTOPHYLMETHIONYLASPARTYLPHENYLALANINAMIDE IN 111; ALCOHOL; ASCORBIC ACID; CHOLECYSTOKININ B RECEPTOR; GENTISIC ACID; METHIONINE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICAL REACTION; CLINICAL ARTICLE; DRUG EXCRETION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HEATING; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; LIGAND BINDING; MALE; OXIDATION; PARAMETER; RADIOACTIVITY; RADIOCHEMICAL PURITY; RADIOLYSIS; RECEPTOR AFFINITY; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; AUTORADIOGRAPHY; CARCINOMA, MEDULLARY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; GASTRINS; HUMANS; ISOTOPE LABELING; MALE; MIDDLE AGED; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, CHOLECYSTOKININ B; THYROID NEOPLASMS;

EID: 56249103484     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.09.006     Document Type: Article

References (35)

1. Reubi J.C., and Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 67 (1996) 644-647
2. Behe M., Reubi J.C., Nock B., Macke H.R., Breeman W.A.P., Bernard H.F., et al. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur J Nucl Med Mol Imaging 32 (2005) P273
3. Behe M., Becker W., Gotthardt M., Angerstein C., and Behr T.M. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 30 (2003) 1140-1146
4. Behe M., and Behr T.M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 66 (2002) 399-418
5. Behr T.M., Jenner N., Behe M., et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40 (1999) 1029-1044
6. Kwekkeboom D.J., Bakker W.H., Kooij P.P., et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27 (2000) 1312-1317
7. Reubi J.C., Waser B., Schaer J.C., et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 25 (1998) 481-490
8. Good S., Walter M.A., Waser B., et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 35 (2008) 1868-1877
9. Breeman W.A., de Jong M., Visser T.J., Erion J.L., and Krenning E.P. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30 (2003) 917-920
10. von Guggenberg E., Dietrich H., Skvortsova I., Gabriel M., Virgolini I.J., and Decristoforo C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1209-1218
11. Mather S.J., McKenzie A.J., Sosabowski J.K., Morris T.M., Ellison D., and Watson S.A. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 48 (2007) 615-622
12. 111In-DOTA-MG11. Technetium, Rhenium and other metals in chemistry in nuclear medicine 7 (2006), SG Editoriali U Mazzi, Padova 231-232
13. Sosabowski J.K., Lee M., Dekker B.A., et al. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci 31 (2007) 102-111
14. de Jong M., Bakker W.H., Bernard B.F., et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 40 (1999) 2081-2087
15. Nock B.A., Maina T., Behe M., et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 46 (2005) 1727-1736
16. Fröberg A., Nock B.A., Maina T., et al. Comparison of 3 radiolabelled peptides for CCK 2-receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2006) S109
17. Liu S., and Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 12 (2001) 7-34
18. Breeman W.A., Kwekkeboom D.J., De Blois E., de Jong M., Visser T.J., and Krenning E.P. Radiolabelled regulatory peptides for imaging and therapy. Anti-Cancer Agents in Medicinal Chemistry 7 (2007) 345-357
19. Maina T., Nock B., Nikolopoulou A., et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 29 (2002) 742-753
20. Bernard B.F., Krenning E., Breeman W.A., et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 21 (2000) 1079-1085
21. Breeman W.A., Kwekkeboom D.J., Kooij P.P., et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 36 (1995) 623-627
22. de Jong M., Breeman W.A., Bernard B.F., et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 26 (1999) 693-698
23. Dubreuil P., Fulcrand P., Rodriguez M., Laur J., Bali J.P., and Martinez J. ACE-like hydrolysis of gastrin analogs and CCK-8 by fundic mucosal cells of different species with release of the amidated C-terminal dipeptide. Biochim Biophys Acta 1039 (1990) 171-176
24. Dubreuil P., Fulcrand P., Rodriguez M., Fulcrand H., Laur J., and Martinez J. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide. Biochem J 262 (1989) 125-130
25. Breeman W.A., Hofland L.J., de Jong M., et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 81 (1999) 658-665
26. Breeman W.A., de Jong M., Kwekkeboom D.J., et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28 (2001) 1421-1429
27. Breeman W.A., de Jong M., Bernard B.F., et al. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83 (1999) 657-663
28. Breeman W.A., VanHagen M.P., Visser-Wisselaar H.A., et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med 37 (1996) 108-117
29. van Hagen P.M., Breeman W.A., Reubi J.C., et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23 (1996) 1508-1513
30. Kung M.P., and Kung H.F. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 32 (2005) 673-678
31. Breeman W.A., de Jong M., de Blois E., Bernard B.F., Konijnenberg M., and Krenning E.P. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 32 (2005) 478-485
32. Velikyan I., Beyer G.J., and Langstrom B. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem 15 (2004) 554-560
33. Blauenstein P., Pfeiffer G., Schubiger P.A., et al. Chemical and biological properties of a cationic Tc-tetraamine complex. Int J Appl Radiat Isot 36 (1985) 315-317
34. Prakash S., Went M.J., and Blower P.J. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Nucl Med Biol 23 (1996) 543-549
35. Reubi J.C., Waser B., Laderach U., et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 112 (1997) 1197-1205